{
    "root": "65ee7bca-fa06-45b3-ac02-2119b92ba347",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pioglitazone",
    "value": "20250318",
    "ingredients": [
        {
            "name": "PIOGLITAZONE HYDROCHLORIDE",
            "code": "JQT35NPK6C"
        },
        {
            "name": "CARBOXYMETHYLCELLULOSE CALCIUM",
            "code": "UTY7PDF93L"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        }
    ],
    "indications": "Monotherapy and Combination Therapy\n                     \n                     Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14)].\n                     \n                     Important Limitations of Use\n                     \n                      Pioglitazone tablets exert its antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings.\n                      Use caution in patients with liver disease [see Warnings and Precautions (5.3)].",
    "contraindications": "• Initiate pioglitazone tablets at 15 mg or 30 mg once daily. Limit initial dose to 15 mg once daily in patients with NYHA Class I or II heart failure. (2.1) • If there is inadequate glycemic control, the dose can be increased in 15 mg increments up to a maximum of 45 mg once daily. (2.1) • Obtain liver tests before starting pioglitazone tablets. If abnormal, use caution when treating with pioglitazone tablets, investigate the probable cause, treat (if possible) and follow appropriately. Monitoring liver tests while on pioglitazone tablets are not recommended in patients without liver disease. (5.3)",
    "warningsAndPrecautions": "Pioglitazone is available in 15 mg, 30 mg, and 45 mg tablets as follows:\n                     \n                     Pioglitazone Tablets USP, 15 mg are white to off-white, round, biconvex, uncoated tablets, debossed with “31” on one side and “H” on other side.\n                  Carton of 100 (10 tablets per blister pack x 10), NDC 0904-7090-61\n                  \n                     \n                     Pioglitazone Tablets USP, 30 mg are white to off-white, round, flat faced, beveled edge uncoated tablets, debossed with “32” on one side and “H” on other side.\n                  Carton of 100 (10 tablets per blister pack x 10), NDC 0904-7096-61\n                  \n                     \n                     Storage\n                     \n                     \n                      Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Keep container tightly closed, and protect from light, moisture and humidity.",
    "adverseReactions": "•Initiation in patients with established NYHA Class III or IV heart failure [see Boxed Warning].\n                     \n                     \n                        • Use in patients with known hypersensitivity to pioglitazone or any other component of pioglitazone tablets."
}